Products

PowerLook® Tomo Detection
iCAD
Oncology AI
PowerLook® Tomo Detection is an AI-powered computer-assisted detection (CAD) software that optimizes digital breast tomosynthesis (DBT) reading efficiency and improves radiologists' confidence in breast cancer detection by reducing reading time and highlighting suspicious areas.
SECOND LOOK ™
iCAD, Inc.
Oncology AI
SECOND LOOK™ by iCAD, Inc. is an FDA-cleared, AI-powered computer-aided detection (CAD) system for mammography, designed to assist radiologists in the early and accurate detection of breast cancer.
PowerLook Tomo Detection V2 Software
iCAD
Oncology AI
PowerLook Tomo Detection V2 Software by iCAD is an FDA-cleared, AI-powered computer-assisted detection (CAD) tool for digital breast tomosynthesis (DBT), designed to help radiologists efficiently identify suspicious breast lesions and calcifications.

See all 5 products →

About iCAD

iCAD is a medical technology company that specializes in providing clinically proven, AI-powered solutions primarily focused on early cancer detection and therapy. For physicians, iCAD’s flagship offering, the ProFound Breast Health Suite, leverages artificial intelligence to enhance mammography analysis for breast cancer detection, automated breast density assessment, and personalized short-term risk evaluation. These tools are designed to integrate seamlessly into existing clinical workflows, aiming to improve diagnostic accuracy, reduce reading times, and optimize patient outcomes by facilitating earlier and more reliable cancer identification.

Following its acquisition by DeepHealth, a wholly-owned subsidiary of RadNet, Inc. in July 2025, iCAD’s extensive AI portfolio is being integrated to further advance AI adoption and expand global access to advanced breast cancer screening and diagnosis technologies. The combined capabilities are expected to offer a comprehensive suite of AI-driven image interpretation and workflow solutions, addressing clinical and operational challenges in screening and diagnosis across over 1,500 healthcare provider locations in more than 50 countries.

What Physicians Need to Know

Breast Cancer Detection
iCAD specializes in AI-powered solutions for early breast cancer detection in both 2D mammography and digital breast tomosynthesis (DBT), accurately identifying malignant soft tissue densities and calcifications.
Breast Density Assessment
Their solutions provide objective, reliable, and consistent breast density scoring, which is crucial for personalized screening plans and informing treatment decisions.
Breast Cancer Risk Evaluation
iCAD offers image-based risk models (ProFound AI Risk) that are significantly more accurate (up to 2.4x) than traditional models for predicting short-term breast cancer risk (1-2 years).
Heart Health Assessment
The ProFound Breast Health Suite can also screen a single mammogram for hidden heart or vascular disease by assessing calcium deposits in breast arteries, a proxy for cardiovascular disease.
Prostate Cancer Detection
iCAD has developed computer-aided detection (CAD) solutions like VividLook for prostate MRI analysis, assisting in distinguishing benign from malignant lesions and pinpointing tumor location and size.
Clinically Proven Accuracy
iCAD's solutions are backed by extensive science, clinical evidence, and proven patient outcomes, with algorithms trained on large, diverse datasets (e.g., over 20 million training images and 88,000 training cases for ProFound AI).
Enhanced Detection Rates
ProFound AI has been shown to significantly increase radiologists' average cancer detection rates (e.g., 63% for general radiologists, 23% for breast subspecialists) while reducing false positives and unnecessary recalls.
Workflow Efficiency
The AI solutions are designed for concurrent reading, rapidly analyzing images and providing crucial information like lesion certainty and case scores to assist in clinical decision-making and prioritizing caseloads, thereby improving workflow efficiency and reducing reading time.
Multi-Vendor Compatibility
iCAD's solutions are known for their broad multi-vendor compatibility, seamlessly integrating into various diagnostic workflows and imaging infrastructures, including different PACS and mammography workstations (e.g., Hologic, Intelerad, Siemens Healthineers, Fujifilm).
Deep Learning Technology
Their core AI algorithms are built with the latest deep-learning and convolutional neural networks for advanced image processing and pattern recognition, enabling the detection of subtle patterns not always visible to the human eye.
Cloud-Based SaaS Model
With ProFound Cloud, iCAD offers its solutions as a Software-as-a-Service (SaaS) platform, providing medical providers with a cost-effective, secure, and scalable means to access and deploy the latest AI technology without significant initial hardware investment.
Google Cloud & Google Health AI Integration
iCAD leverages Google Cloud for its ProFound Cloud platform and has a strategic partnership with Google Health to integrate Google's AI technology, enhancing its breast imaging solutions and expanding global access.
NVIDIA AI Enterprise Stack
iCAD utilizes the NVIDIA AI Enterprise Stack for running its AI applications in data centers, indicating a robust infrastructure for high-performance computing and real-time reads.
Physician Tip

iCAD's ProFound Breast Health Suite empowers physicians to achieve earlier cancer detection with greater accuracy, significantly reduce reading time, and increase diagnostic confidence. The AI acts as a 'physician-assisted AI,' highlighting suspicious areas and providing certainty scores, which can lead to reduced unnecessary recalls and biopsies, and ultimately improve patient outcomes. The ability to personalize screening plans through precise density assessment and short-term risk evaluation, combined with seamless integration into existing workflows and multi-vendor compatibility, ensures a smooth and efficient adoption into clinical practice.

iCAD's solutions are designed for seamless integration into existing diagnostic workflows and are compatible with a wide range of multi-vendor environments, including various Picture Archiving and Communication Systems (PACS) and mammography workstations (e.g., Hologic, Intelerad, Siemens Healthineers, Fujifilm). They also have strategic partnerships with platforms like Microsoft's Precision Imaging Network and PowerScribe for broader access and streamlined AI-based reporting.

Products by iCAD

5 products in the directory

PowerLook® Tomo Detection
iCAD
Oncology AI
PowerLook® Tomo Detection is an AI-powered computer-assisted detection (CAD) software that optimizes digital breast tomosynthesis (DBT) reading efficiency and improves radiologists' confidence in breast cancer detection by reducing reading time and highlighting suspicious areas.
SECOND LOOK ™
iCAD, Inc.
Oncology AI
SECOND LOOK™ by iCAD, Inc. is an FDA-cleared, AI-powered computer-aided detection (CAD) system for mammography, designed to assist radiologists in the early and accurate detection of breast cancer.
PowerLook Tomo Detection V2 Software
iCAD
Oncology AI
PowerLook Tomo Detection V2 Software by iCAD is an FDA-cleared, AI-powered computer-assisted detection (CAD) tool for digital breast tomosynthesis (DBT), designed to help radiologists efficiently identify suspicious breast lesions and calcifications.
PowerLook Density Assessment
iCAD
Clinical Decision Support & Reference
PowerLook® Density Assessment is an automated breast density software by iCAD that analyzes digital mammograms to provide objective BI-RADS® 5th Edition breast density categories, aiming to standardize assessments and personalize breast cancer screening.
ProFound Detection
iCAD, Inc.
Oncology AI
AI-powered solution for digital breast tomosynthesis (DBT) that enhances breast cancer detection, reduces false positives, and aids radiologists in identifying suspicious lesions.

What the Web Says

iCAD, recently acquired by DeepHealth (a RadNet subsidiary), is a company specializing in AI-powered breast cancer detection and workflow solutions. Their ProFound AI technology is designed to improve diagnostic accuracy, reduce reading times for radiologists, and lower recall rates for non-cancer cases. While product reviews are generally positive, highlighting the effectiveness and flexibility of their AI solutions, company reviews from employees are mixed, with concerns about management and work-life balance.

Overall: Mixed

Strengths

  • ProFound AI improves radiologist confidence and helps find more cancers while reducing false positives.
  • The AI solution supports multiple output formats, offering flexibility for integration with existing systems like Hologic workstations or Inteleradu00ae PACS.
  • iCAD's technology is considered high-level and enhances workflow for radiologists.
  • The company has an extensive portfolio deployed in over 50 countries and 1500 provider sites, accelerating global AI adoption.
  • Some employees appreciate the inclusive work environment and the feeling of helping save lives.
  • The products are described as solid and functional.

Limitations

  • Employee reviews indicate issues with HR and management, describing them as disorganized and inconsistent.
  • Work-life balance is a concern for some employees, with some reporting it as non-existent.
  • There are complaints about pay and benefits, including a lack of raises for several years and a minimal benefits package.
  • Communication and support among teams can be lacking.
  • Upper management is perceived as clueless and not valuing employees.
  • There are not enough product reviews on platforms like G2 to provide comprehensive buying insight for all iCAD products.

Based on reviews from: G2, Indeed.com, DeepHealth (via icadmed.com), Imaging Technology News, BioWorld, YouTube

Last updated: 2026-07-18

Videos

News, demos, and interviews about iCAD.

Loading videos...

Videos load interactively. If none appear, search YouTube for iCAD →

View all on YouTube

Press & Coverage

iCAD
RadNet's Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of iCAD
RadNet's subsidiary, DeepHealth, completed the acquisition of iCAD, integrating iCAD's commercial, technology, and regulatory capabilities to advance AI-powered breast health solutions. This acquisition expands DeepHealth's market access to over 1,500 healthcare provider locations worldwide, aiming to scale its impact to over 10 million mammograms annually.
2025-07
BioWorld
Deephealth closes $110M Icad buy, gains Techlive clearance | BioWorld
DeepHealth Inc., a RadNet subsidiary, finalized the acquisition of iCAD Inc. in a $110 million all-stock transaction, also receiving U.S. FDA 510(k) clearance for Techlive, a remote scanning solution. This acquisition positions DeepHealth as an umbrella brand for RadNet's digital health segment, incorporating various AI solutions for different health areas.
2025-08
Femtech Insider
RadNet's DeepHealth Completes Acquisition of AI Breast Health Company iCAD
RadNet's DeepHealth completed its acquisition of iCAD, a provider of AI-powered breast health solutions, integrating iCAD's AI portfolio for breast cancer detection, risk evaluation, breast density assessment, and breast arterial calcification analysis. The acquisition is expected to expand DeepHealth's market reach to over 10 million mammograms annually and accelerate AI adoption in breast cancer screening programs globally.
2025-08
iCAD
iCAD Collaborates with Microsoft to provide access to its Mammography Solutions in Microsoft's Precision Imaging Network (PIN)
iCAD announced a collaboration with Microsoft to integrate its AI-powered mammography solutions into Microsoft's Precision Imaging Network (PIN), offering automated patient reporting through PowerScribe integration. This collaboration will cloud-host iCAD's ProFound AI Breast Health Suite on Microsoft's network, aiming to enhance breast health detection and streamline clinical workflows.
2025-04
iCAD
iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024
iCAD showcased its AI breast health technologies at RSNA 2024, highlighting the FDA-cleared ProFound Detection Version 4 and a new partnership with Cascaid Health to expand access to AI-driven breast health solutions through a virtual care model called ProFound Health. ProFound Detection Version 4.0 for Digital Breast Tomosynthesis (DBT) received FDA clearance in November 2024.
2024-11
Healthcare Dive
Google expands AI mammography deal with iCAD - Healthcare Dive
Google's health division expanded its agreement with iCAD to integrate its AI technology into iCAD's 2D mammography suite, extending the licensing agreement from five to 20 years. This partnership aims to allow iCAD's ProFound Breast Health Suite to serve as a second reader in breast cancer screenings, pending regulatory clearance.
2023-08
iCAD
iCAD Reports Financial Results for First Quarter Ended March 31, 2025
iCAD reported Q1 2025 financial results with a total Annual Recurring Revenue (ARR) of $10.7 million, an 18% year-over-year increase, and Q1 revenues of $4.9 million. The company also announced an improved gross profit margin of 86% and closed 92 total deals, including 19 ProFound Cloud implementations.
2025-05
iCAD
RadNet, Inc. to Acquire iCAD, Inc. to Accelerate AI-Powered Early Detection and Diagnosis of Breast Cancer
RadNet, Inc. announced a definitive merger agreement to acquire iCAD in an all-stock transaction, valued at approximately $103 million, or $3.61 per share. This acquisition aims to accelerate AI-powered early detection and diagnosis of breast cancer.
2025-04

Frequently Asked Questions

iCAD primarily offers the ProFound Breast Health Suite, which includes AI-powered solutions for 2D and 3D mammography for cancer detection, breast density assessment, and personalized short-term breast cancer risk evaluation. Their latest version, ProFound Detection 4.0, is FDA-cleared and significantly improves the detection of aggressive cancers. Additionally, iCAD is developing a Heart Health solution to identify breast arterial calcifications and has a legacy product, VeraLook, for colon polyp detection.
iCAD's ProFound AI Detection is FDA-cleared in the U.S., CE Marked in Europe, and Health Canada Licensed, demonstrating adherence to key medical device regulations. While ProFound AI Risk is CE Marked and Health Canada Licensed, it is currently for investigational use only in the U.S. and not FDA-cleared. iCAD's privacy policy indicates compliance with applicable data protection laws, noting that personal data may be processed and transferred to the United States.
iCAD has transitioned towards a Software-as-a-Service (SaaS) business model, offering its ProFound Cloud solutions via subscription. This subscription model aims to provide healthcare organizations with lower upfront costs, accelerated deployment, and easier access to new functionalities and algorithm updates without significant capital outlays.
iCAD provides comprehensive customer support through a dedicated call center, accessible via phone and email. They also offer a customer portal for self-service options, including ticket management, a knowledge base, and access to user manuals, release notes, and product training. Their support team specializes in PACS/RWS connectivity, CAD workflow, and DICOM integration to ensure efficient implementation and troubleshooting.
iCAD has established significant partnerships to expand its AI capabilities and market presence. Notably, they partnered with Google Health to enhance breast cancer AI solutions and leverage Google Cloud's infrastructure. Other key collaborations include partnerships with CancerIQ for breast health, Densitas for mammography quality and risk evaluation, and deepc for integrating their ProFound AI Breast Health Suite into deepcOS.
iCAD, Inc. was acquired by RadNet, Inc. in an all-stock transaction valued at approximately $103 million, with the merger expected to close in the second or third quarter of 2025. Following the acquisition, iCAD will be integrated into RadNet's wholly-owned AI subsidiary, DeepHealth, aiming to combine complementary AI technologies and accelerate growth in cancer screening. This strategic move positions iCAD's solutions within a larger diagnostic imaging services provider, potentially enhancing its long-term stability and market reach.

Investors

Who's funded iCAD.

Related Companies

Clarista is a healthcare AI company that focuses on building a “trust layer” for enterprise AI, particularly within regulated industries like healthcare and financial services. The company’s platform aims to address the challenges of data fragmentation, governance, and compliance that often hinder the successful implementation of AI projects in large organizations. Clarista’s technology unifies structured […]

HelloBooks.ai is an AI-powered accounting software company that aims to automate and simplify financial management for small businesses, freelancers, and accounting professionals. The platform utilizes generative AI to handle repetitive bookkeeping tasks such as transaction categorization, receipt capture, bank reconciliation, and report generation. It is designed to reduce manual data entry and improve accuracy, allowing […]

Vero, also known as Vero.ai, is an artificial intelligence company specifically designed to augment clinical workflows and improve patient care within the healthcare sector. Their primary focus is on leveraging AI to streamline administrative tasks, enhance diagnostic accuracy, and personalize treatment plans. By automating routine processes, Vero aims to free up healthcare professionals’ time, allowing […]

Ant Group, a global digital technology provider and operator of Alipay, has significantly expanded its focus into healthcare AI. The company recently upgraded its physician platform, Haodf for Doctor, into ‘AQ for Doctor,’ an AI-powered workstation designed to support physicians across various stages of clinical practice, including online consultations, patient management, clinical decision support, and […]

e4health is a healthcare consulting and services company that provides innovative solutions to hospitals, health systems, outpatient providers, and physician practices. The company focuses on addressing data, quality, and revenue challenges within the healthcare ecosystem. Their services are designed to streamline health information data and workflows, optimize coding, quality, and clinical documentation integrity processes, and […]

PayZen is a healthcare AI company dedicated to solving the healthcare affordability crisis for both patients and providers. The company’s AI-powered platform offers personalized, interest-free, and fee-free patient financing solutions, enabling patients to manage their medical bills through affordable payment plans tailored to their unique ability to pay. This approach aims to increase access to […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.